{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:45Z","timestamp":1761895005139},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.patbio.2009.06.005","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T18:33:41Z","timestamp":1259346821000},"page":"e89-e92","source":"Crossref","is-referenced-by-count":6,"title":["JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: Contribution, diagnosis and therapeutic prospects"],"prefix":"10.1016","volume":"59","author":[{"given":"A.","family":"Benmoussa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nadifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2009.06.005_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO;2-5","article-title":"Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response","volume":"20","author":"Eibl","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.patbio.2009.06.005_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2009.06.005_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.patbio.2009.06.005_bib4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2009.06.005_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.patbio.2009.06.005_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.E02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain","volume":"14","author":"Saharinen","year":"2003","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.patbio.2009.06.005_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"key":"10.1016\/j.patbio.2009.06.005_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(01)00398-7","article-title":"Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases","volume":"8","author":"Zhou","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.patbio.2009.06.005_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (V617F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2009.06.005_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.patbio.2009.06.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biomet\/6.1.1","article-title":"Test sudent the probale error of a mean","volume":"6","author":"Gusset","year":"1908","journal-title":"Biometrika"},{"key":"10.1016\/j.patbio.2009.06.005_bib12","first-page":"1053","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","author":"Speletas","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.patbio.2009.06.005_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2009.06.005_bib14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplasticsyndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2009.06.005_bib15","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"Biol Chem"},{"issue":"14","key":"10.1016\/j.patbio.2009.06.005_bib16","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMx070051","article-title":"Stratton A: Jak2 exon12 mutation in polycythemia vera and idiopathic erythrocytosis","volume":"357","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2009.06.005_bib17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders:a study of 1182 patients","volume":"10","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2009.06.005_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2009.06.005_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.patbio.2006.06.004","article-title":"The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders","volume":"55","author":"Kiladjian","year":"2007","journal-title":"Pathologie Biologie"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811409001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811409001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T01:50:15Z","timestamp":1544838615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811409001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0369811409001199"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2009.06.005","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}